0000000000178277

AUTHOR

Ildegarda Campisi

showing 8 related works from this author

Estrogen regulates cytokine production and apoptosis in PMA-differentiated, macrophage-like U937 cells

2003

We have investigated the effects of sex steroids, estradiol (E2), and testosterone (T) on the synthesis of tumor necrosis factor alpha (TNF-alpha) and interleukin-10 (IL-10) in phorbol-myristate-acetate (PMA)-differentiated human monoblastic U937 cells. The ability of both hormones to modulate the viability and programmed cell death of macrophage-like PMA-differentiated U937 cells was also inspected. E2 increased TNF-alpha synthesis, whereas T had no effect on the production of this cytokine. The combination of E2 and its antagonist tamoxifen or ICI-182,789 completely abolished the induction of TNF-alpha, while combination of T and its antagonist Casodex (CSDX) did not significantly affect …

medicine.medical_specialtyProgrammed cell deathmedicine.drug_classmedicine.medical_treatmentCell BiologyBiologyBiochemistryCell biologyInterleukin 10CytokineEndocrinologyEstrogenApoptosisInternal medicinemedicineMacrophageTumor necrosis factor alphaIL-2 receptorMolecular BiologyJournal of Cellular Biochemistry
researchProduct

Expression Levels and Clinical-Pathological Correlations of HER2/neu in Primary and Metastatic Human Breast Cancer

2005

In this retrospective study we assessed the expression of the HER2/neu oncogene product in a series of 574 consecutive breast cancer cases, all recruited at the Maurizio Ascoli Cancer Center of Civico Hospital, in Palermo, between January 1998 and June 2003. The HER2/neu expression was evaluated using immunohistochemistry and scored from 0 to +3 as per FDA recommendations. The HER2/neu expression levels were related to the clinical-pathological features of the disease, including tumor size, nodal and menopausal status, estrogen and progesterone receptors, and hormonal or chemotherapeutic treatment. In 108 patients with a follow-up period of 3 years or more, the HER2/neu expression was also …

AdultOncologymedicine.medical_specialtyTime FactorsReceptor ErbB-2medicine.drug_classBreast NeoplasmsDisease-Free SurvivalGeneral Biochemistry Genetics and Molecular BiologyHER2/neuBreast cancerHistory and Philosophy of ScienceInternal medicineBiomarkers TumormedicineHumansNeoplasm Metastasisskin and connective tissue diseasesPathologicalIn Situ Hybridization FluorescenceAgedRetrospective StudiesbiologyOncogenebusiness.industryGeneral NeuroscienceCancerRetrospective cohort studyMiddle Agedmedicine.diseaseImmunohistochemistryGene Expression Regulation NeoplasticTreatment OutcomeEstrogenLymphatic Metastasisbiology.proteinImmunohistochemistryFemalebusinessAnnals of the New York Academy of Sciences
researchProduct

Sex steroids, carcinogenesis, and cancer progression

2004

The relationship between sex steroids and cancer has been studied for more than a century. Using an original intact cell analysis, we investigated sex steroid metabolism in a panel of human cancer cell lines, either hormone responsive or unresponsive, originating from human breast, endometrium, and prostate. We found that highly divergent patterns of steroid metabolism exist and that the catalytic preference (predominantly reductive or oxidative) is strictly associated with the steroid receptor status of cells. We explored intra-tissue concentrations and profiles of estrogens in a set of human breast tumors as compared to normal mammary tissues, also in relation to their estrogen receptor s…

Receptor StatusTime FactorsIntratumor estrogenCatecholsBreast cancer; Intratumor estrogens; Sex steroids; Adsorption; Androstenedione; Animals; Breast Neoplasms; Catalysis; Catechols; Cell Line Tumor; Chromatography High Pressure Liquid; Disease Progression; Estradiol; Estrogens; Humans; In Vitro Techniques; Ions; Kinetics; Models Biological; Neoplasms; Steroids; Time Factors; Biochemistry Genetics and Molecular Biology (all)Sex steroidmedicine.disease_causeEndometriumCatalysiBreast cancerNeoplasmsEstrogen Receptor StatusChromatography High Pressure LiquidEstradiolGeneral NeuroscienceSex hormone receptormedicine.anatomical_structureDisease ProgressionSteroidsBreast NeoplasmHumanmedicine.medical_specialtyTime FactorBreast NeoplasmsIn Vitro TechniquesBiologyModels BiologicalCatalysisGeneral Biochemistry Genetics and Molecular BiologyBreast cancerHistory and Philosophy of ScienceCell Line TumorInternal medicinemedicineAnimalsHumansIonSteroidKineticIonsBiochemistry Genetics and Molecular Biology (all)AnimalIn Vitro TechniqueAndrostenedioneCancerEstrogensmedicine.diseaseEstrogenKineticsEndocrinologySex steroidCatecholNeoplasmAdsorptionCarcinogenesis
researchProduct

CCR5 Proinflammatory Allele in Prostate Cancer Risk

2009

Prostate cancer (PCa) is the most common malignant neoplasm in older men in Western countries. The number of affected older men is increasing. Therefore, strategies for prevention of prostate cancer are crucial. To this purpose it is essential to know the mechanisms involved in development and progression of this malignancy. Recently, an increasing body of genetic and epidemiological studies proposed new hypotheses for prostate carcinogenesis. It has been suggested that genetic factors as well as exposure to environmental factors such as infectious agents, dietary carcinogens, and hormonal imbalances participate in PCa development. Besides, chronic inflammation plays a key role in PCa. Taki…

MaleOncologyProstate Cancer Inflammation CCR5delta32 deletionmedicine.medical_specialtyReceptors CCR5Pilot ProjectsInflammationBiologyMalignancyGeneral Biochemistry Genetics and Molecular BiologyProinflammatory cytokineProstate cancerHistory and Philosophy of ScienceProstateInternal medicineMolecular geneticsEpidemiologymedicineHumansAlleleAllelesAgedSettore MED/04 - Patologia GeneraleAged 80 and overGeneral NeuroscienceProstatic Neoplasmsmedicine.diseasemedicine.anatomical_structureImmunologyInflammation Mediatorsmedicine.symptomAnnals of the New York Academy of Sciences
researchProduct

A Pilot Study on Prostate Cancer Risk and Pro-Inflammatory Genotypes: Pathophysiology and Therapeutic Implications

2010

Host genetic factors are crucial risk determinants for many human cancers. In this framework, an interesting model is represented by prostate cancer (PC), which is featured by a complex pathophysiology with a strong genetic component. Multiple genes seem to influence PC risk and several single nucleotide polymorphisms (SNPs) of candidate genes modifying PC susceptibility have been identified. It is noteworthy the potential association of common SNPs in pro-inflammatory genes with PC risk, since chronic inflammation is assumed to play a key role in prostate carcinogenesis. With the aim to identify candidate genes as an experimental basis to develop new strategies for both prevention and trea…

MaleCandidate geneGenotypePilot ProjectsSingle-nucleotide polymorphismBioinformaticsPolymorphism Single NucleotideProstate cancerRisk FactorsDrug DiscoveryGenotypemedicineHumansSNPSettore MED/05 - Patologia ClinicaGeneAgedAged 80 and overInflammationPharmacologySettore MED/04 - Patologia Generalebusiness.industryProstatic NeoplasmsCancerMiddle AgedProstate cancer (PC) inflammation genetics TLR4 TLR2 PTGS2 5-LO SNP.medicine.diseaseImmunologyTLR4Inflammation Mediatorsbusiness
researchProduct

Androgen metabolism and biotransformation in nontumoral and malignant human liver tissues and cells

2009

There is indirect multiple evidence that hints at a potential role of sex steroids in development and progression of human hepatocellular carcinoma (HCC). In the present study, we have investigated androgen metabolism in a panel of human liver cancer cell lines (HA22T, Huh7, HepG2) and in normal, cirrhotic and malignant human liver tissues aiming to dissect the potential impact of individual enzyme activities and their products in normal and diseased human liver, both in vivo and in vitro. Using our intact cell analysis we were able to assess rates and pathways of androgen metabolism in living conditions. Overall, incubation of cultured cells or tissue minces with either testosterone (T) or…

Malemedicine.medical_specialtyCarcinoma Hepatocellularmedicine.drug_classEndocrinology Diabetes and MetabolismClinical BiochemistryBiochemistryEndocrinologyAromataseInternal medicineCell Line TumormedicineHumansTestosteroneAromataseMetabolism estrogenandrogen normal liver liver cirrhosisMolecular BiologyTestosteroneAromatase inhibitorbiologyAromatase InhibitorsLiver cellLiver NeoplasmsAndrostenedioneCell BiologyAndrogenmedicine.anatomical_structureEndocrinologyLiverSelective estrogen receptor modulatorEstrogenHepatocytebiology.proteinAndrogensMolecular MedicineFemale
researchProduct

Target therapy in HER2-overexpressing breast cancer patients.

2011

The development of new therapeutic strategies, such as monoclonal antibodies directed against human epidermal growth factor receptor-2 (HER2), has offered new hopes for women with early breast cancer whose tumors overexpress HER2. We retrospectively analyzed the population-based data of Breast Cancer Registry of Palermo in 2004-2006, and selected 1401 invasive breast cancer cases, nonmetastatic at diagnosis, having HER2/neu oncogene expression determined. We have correlated this information to age, tumor stage at diagnosis (TNM), nodal involvement, and receptor status (ER and PgR). Survival analysis was conducted dividing the patients in two different groups according to date of diagnosis: …

OncologyAdultmedicine.medical_specialtyReceptor StatusReceptor ErbB-2PopulationAntineoplastic AgentsBreast NeoplasmsKaplan-Meier EstimateAntibodies Monoclonal HumanizedBiochemistryBreast cancerTrastuzumabInternal medicineGeneticsmedicineHumansMolecular Targeted Therapyskin and connective tissue diseaseseducationMolecular BiologySurvival analysisAgedNeoplasm StagingRetrospective StudiesAged 80 and overeducation.field_of_studybiologybusiness.industryAntibodies MonoclonalRetrospective cohort studyMiddle AgedTrastuzumabmedicine.diseasePrognosisMonoclonalbiology.proteinMolecular MedicineFemaleAntibodybusinessBiotechnologymedicine.drugOmics : a journal of integrative biology
researchProduct

Application of a new classification to a breast tumor series from a population-based cancer registry: demographic, clinical, and prognostic features …

2009

A new classification based on gene expression profiling or immunohistochemical (IHC) characteristics may replace current histopathological classifications and predict better clinical outcomes. We used IHC markers to classify incident cases ascertained by the Palermo Breast Cancer Registry (2002-2004) into four subtypes: luminal-A (ER+ or PgR+ and HER2/neu-); luminal-B (ER+ or PgR+, HER2/neu+); basal-like (ER-, PgR-, HER2/neu-); and HER2+/ER- (HER2/neu+, ER-, PgR-). We evaluated HER2/neu, ER and PgR in 1300/1985 (65%) cases. The most common IHC-subtype was luminal-A (68%), whereas luminal-B, basal-like, and HER2+/ER- accounted for 14%, 13%, and 5%, respectively. IHC-subtypes were not associa…

Oncologymedicine.medical_specialtyBreast NeoplasmsPopulation basedGeneral Biochemistry Genetics and Molecular BiologyBreast tumorBreast cancerHistory and Philosophy of ScienceInternal medicinemedicineHumansRegistriesskin and connective tissue diseasesGrading (tumors)DemographyGynecologyTumor sizebusiness.industryGeneral NeuroscienceGenes erbB-2Middle Agedmedicine.diseasePrognosisImmunohistochemistryCancer registryMenopauseItalyReceptors EstrogenPopulation SurveillanceImmunohistochemistryFemalebusinessReceptors ProgesteroneAnnals of the New York Academy of Sciences
researchProduct